RoslinCT and Ayrmid Ltd. Announce Expansion of Strategic Partnership to Manufacture Omisirge® (omidubicel-onlv) for Second FDA-Approved Indication in Severe Aplastic Anemia (SAA)

Contributed by: Business Wire

Logo

Tags

Research

FDA

Genetics

Clinical Trials

Cardiology

Biotechnology

Health

Pharmaceutical

Science

Ayrmid, Gamida Cell

More Like This

RoslinCT and Ayrmid Pharma Ltd. Announce Their Intent to Enter Into a Strategic Partnership to Manufacture FDA Approved Cell Therapy Omisirge® (omidubicel-onlv)

RoslinCT and BOOST Pharma Announce Strategic Manufacturing Agreement to Advance Cell Therapy for Infants with Osteogenesis Imperfecta

Sangamo Therapeutics Announces U.S. FDA Alignment on Abbreviated Pathway to Potential Approval and EMA Prime Eligibility for ST-920 in Fabry Disease

RoslinCT Awarded £7.25 million Scottish Enterprise R&D Grant to Advance Digital Cell Therapy Manufacturing

The IRO platform

Ori Biotech Announces 10-year, $120M Partnership to Advance Automated Manufacturing for Commercial Cell Therapies

Ori Biotech Announces First Customer Deliveries of IRO to Leading CDMOs and Commercial CGT Manufacturers

CCRM, OmniaBio and Avectas Partner to Improve Cell Therapy Manufacturing

Ori Biotech Expands Team to Advance IRO Commercialization and Industry Partnerships